Warning Letter. We note that you are the sponsor and the clinical investigator for Studies 1 and 2, while a third party is the sponsor of Study 3.

Similar documents
Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

Jose Giron 5/19/16. Protecting and Promoting Your Health. Public Health Service Food and Drug Administration Silver Spring, MD WARNING LETTER

JI) C~ ~~cl MAR WARNING LETTER VIA FEDERAL EXPRESS

FDA approval of emergency expanded access use may be requested by telephone, facsimile, or other means of electronic communications.

Investigator-Initiated INDs

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical

Office for Human Subject Protection. University of Rochester

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use

Our inspection revealed that several important protocol directives were not followed, resulting in significant deviations from the protocol.

Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist

Warnins Lette! SEP

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015

SERIOUS ADVERSE EVENTS

2015 > Soft Computer Consultants, Inc. 4/30/15

Standard Operating Procedures Guidelines for Good Clinical Practice

SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES

Long-Term Follow-Up in Gene Transfer Clinical Research

Assignment Process District or headquarters will send assignment to field inspectors - will include pertinent documents (e.g.:ind, Drug Master File, c

PHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008

GOOD CLINICAL PRACTICE (GCP) Series Catalog

US FDA: CMC Issues for INDs

Expanded Access and the Individual Patient IND

Expanded Access to Investigational Imaging Drugs

External IRB Review What Does it Mean for Your Institution

IND IND ACKNOWLEDGEMENT

The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement

Volunteering for Clinical Trials

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

10-CBA providing access to unlicensed cord blood units

Objectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder

IND Exemption, Preparation and Maintenance. Bruce K. Burnett, PhD, RAC (US, EU) Director, Regulatory Affairs Duke University

Introduction to Clinical Research

Streamlining IRB Procedures for Expanded Access

Investigator Manual. Human Subjects Protection Program

Inspections, Compliance, Enforcement, and Criminal Investigations

ClinicalTrials.gov Registration Guide

EIGHT BASIC ELEMENTS OF INFORMED CONSENT

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

Source And Regulatory Documentation for DMID Clinical Studies

1 The Clinical Research Coordinator (CRC)... 1

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Applicability of US Regulations to Canadian Research

MRCTCenter ExpandedAccess InvestigationalProducts. PracticalApproach Sponsors,Physicians, InstitutionalReview Boards. Boards. Framework Framework

De Novo Classification Process (Evaluation of Automatic Class III Designation) Guidance for Industry and Food and Drug Administration Staff

Compliance Department RESEARCH COMPLIANCE MEMORANDUM

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE

Guidance for Industry Postmarketing Studies and Clinical Trials Implementation of Section 505(o) of the Federal Food, Drug, and Cosmetic Act

FDA > CDRH > CFR Title 21 Database Search

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

DRUG ORDERING AND MAINTENANCE

Determining Patient Access to Investigational Drugs in the US

EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER

TITLE: Research Pharmacy Standard Policy SOP #: INV-100 Page: 1 of 5 Effective Date: 8/31/17

Preparing your Audit Response Communication with the Central Office

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

Expanded Access (including Emergency Use & Humanitarian Use Devices)

How Data Managers Support Prospective Research

Challenges In Cell Product Labeling, Tracking And Traceability

Rules of Human Experimentation

INSTRUCTIONS: HOW TO COMPLETE THE AVASTIN PATIENT

National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services

Acting Deputy Commissioner for Operations, U.S. Food and Drug Administration

FDA Audit Preparation

FDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies

CDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA

Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS

Regulatory and ethical requirements in medical device studies. Finland

INVESTIGATOR HANDBOOK

Source Documents and Regulatory Binders October 6, 2016

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance

TOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH

REGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts

Topics. Safety First Initiative. Drug Safety Communications DRUG SAFETY INITIATIVES AT THE FOOD AND DRUG ADMINISTRATION

Cell and Gene Therapy Medicinal Product Management Act (Draft) General Information

Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff

THE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE

Rochester Institute of Technology Institutional Biosafety Committee (IBC) Guidelines for Committee Authority, Structure and Responsibilities

21 CFR Ch. I ( Edition) Personnel Design controls Identification Traceability.

Canadian Cancer Clinical Trials Network Portfolio Eligibility Criteria and Guidelines

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Florida State University Policy 7-IRB-

Trends in Oversight of Human Research Protections?

University of Virginia Cancer Center

April 13, Background

Investigator Manual HRP-103

Medical Device Purchasing Controls Challenges of Compliance in a World Market June, 2013 OMTEC

FSC Forest Management Group System Procedures

50 SHADES OF GRAY: WHY AND WHEN IS IRB APPROVAL REQUIRED?

Terms of Engagement SW London Collaborative Staff Bank

Human Research Protection Program Guidance for Human Research Determination

Good Clinical Practice

SUBSTANCE ABUSE POLICY

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

Defining Clinical Benefit in Clinical Trials: FDA Perspective

Beth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group

What is an IRB (Institutional Review Board)?

GCP Basics - refresher

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)

Transcription:

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Bv Certified Mail - Return Receipt Reauested And Bv Facsimile Transmission Food and Drug Administration Center for Biikqii Evaluation and Research 1401 Radcvilk Pike Rockville MD 20852-1448 CBER - 04-007 Robert 0. Dillman, M.D. Hoag Cancer Center Hoag Memorial Hospital Presbyterian One Hoag Drive, Building 41 Newport Beach, California 92658-6100 Dear Dr. Dillman: Warning Letter UAY 14 2004 This letter describes the results of a Food and Drug Administration (FDA) inspection that was conducted from December 9,2003, to January 162004. FDA investigator Gene Arty reviewed your activities as a sponsor and clinical investigator testing investigational products in the following studies: l Protocol CBRG 98-09: lntralesional Adoptive Cellular Therapy of Gliomas with Interleukin-2Stimulated Lymphocytes. (hereinafter Study 1) l Phase II Study of a TGF-62 Antisense Gene Modified Allogeneic Tumor Cell Vaccine in patients with Stage-IV Non-Small Cell Lung Cancer. (hereinafter Study 3) We note that you are the sponsor and the clinical investigator for Studies 1 and 2, while a third party is the sponsor of Study 3. FDA conducted this inspection under the agency s Bioresearch Monitoring Program that includes inspections designed to review the conduct of clinical research involving investigational drugs. The investigator issued to you a Form FDA 483, lnspectional Observations, and discussed with you his observations at the conclusion of the inspection. We reviewed the Form FDA 483, the inspection report, and associated Investigational New Drug Application (IND) documents. FDA has not received from you a response to the observations noted in the Form FDA 483.

Page 2 - Dr. Dillman We have determined that you violated regulations governing the proper conduct of clinical studies involving investigational new drugs, as published in Title 21, -- Code of Federal Regulations (CFR), Part 312 (available at http://www.access.apo.aov/narakfr/index.html). The applicable provisions of the CFR are cited for each violation listed below. Some of the violations were not cited on the Form FDA 483, but were evident from the documents that the FDA investigator collected during the inspection. Sponsor responsibilities: 1. You shlpped the investigational drug to investigators not partlclpating in the investigation. [ 21 CFR 5 312.53(b) ] With respect to Study 2, your study records indicate that you manufactured and shipped investigational to two investigators who were not mentioned in your IND or subsequent amendments, in that: Between 1 l/23/98 and 1 /I 8/02, you manufactured and shipped at least 12 lproductfor use by subject- B. During the inspection you provided signed documents admitting that you manufactured the investigational m for both of these subjects because the former manufacturer of a similar product ceased operations in 1998. to this letter, please describe your role and the roles of Drs. regarding the management of these subjects in this study. 2. You failed to obtain signed investigator statements from the investigators participating in the investigation [ 21 CFR 9 312.53(c)(l) ] and failed to submit a protocol amendment to FDA when you added these investigators [21 CFR 5 312.30(c) 1. As indicated in item you failed to obtain signed Drs. m According to your records, Drs su lpervised the administration of the you included sub ectsmandmin a Study 2 report that you submitted to your IND on] You did not amend the IND to notify FDA that you had added new investigators.

Page 3 - Dr. Dillman Clinical investiqator responsibilities: 3. You failed to protect the rights, safety, and welfare of subjects under your care, and you failed to ensure that the investigation was conducted according to the investigational plan and the signed investigator statement. [Zl CFR 312.601. A. The Study 1 protocol limited enrollment to 40 subjects with recurrent tumor and 40 subjects with primary tumor. However, you enrolled and treated at least 42 subjects with recurrent tumor in the study. B. According to the study records, the recurrent arm of the study was closed to subject accrual on 7/30/02. However, on g/5/02 you enrolled subject m whose brain tumor was diagnosed as multiforme according to the operation notes dated, C. The Study 1 protocol requires the evaluation of subjects one month after infusion of the investigational autologous LAK cells. You failed to perform such evaluation for several subjects. The table Day O-30 Toxicity Data indicates that subjects ere not examined one month after infusion. We request that you provide a table documenting the follow-up evaluations for these subjects as part of your response to this letter. D. Your investigator statement required the identification of all subinvestigators. You did not identify Dr.- or Dr. sub-investigators for Study 1 on a Form FDA-1572. Drs. discussed the study and obtained the informed consent for I subject and- respectively. 4. You failed to maintain adequate and accurate case histories. [ 21 CFR 0 312.62(b) 1. A. Toxicities occurring within the first month following infusion of the investigational cells in Study 1 were not graded in a timely manner. For example, subject-was administered the investigational drug on -yet you did not assure that the Toxicity Grading Form was completed until 2/24/03. In addition, the form indicated that toxicities were to be recorded as grade 0 to 5. NR was entered as toxicity ratings for several criteria; the meaning of NR is unclear.

Page 4 - Dr. Dillman B. The Study 3 protocol required exclusion of subjects who tested positive for HIV. There was no source documentation to support the results of such testing for subject m C. The Study 1 protocol re uired that investi ational autolo ous LAK c Ils be ccor trig tot 8 LAK reinfusion datasheet, the investigational product for subject * j;,e suspended in a volume ofml for administration via a operative report does not document the volume administered to the subject. 5. You failed to maintain adequate records of the disposition of the drug, [ 21 CFR 0 312.62(a) 1. You failed to maintain adequate vaccine accountability records indicating the receipt, use, disposition, and number of vials remaining for each of the cell lines used in the investigational product preparation for administration to subjects in product accountability information of the vaccine for at least six enrolled in the study indicating, sed or destroyed. 6. You failed to assure that the Institutional Review Board (IRB) would be responsible for the initial and continuing review and approval of the proposed clinical studies and falled to report promptly all changes In the research activity and all unanticipated problems Involving risk to human subjects. [ 21 CFR 5 312.66 ]- A. You failed to submit a protocol amendment to the IRB requesting to increase the number of enrolled subjects in the recurrent arm of Study 1, as indicated in item 3A above. B. The IRB requires all serious or unanticipated adverse reactions (serious adverse events [SAE], including death, hospitalization or serious illness), whether or not study related, to be reported no later than five days after the adverse reaction has been recognized. You did not report the following serious adverse events at all or within the required time frame: Subject LAK cell SAE Date of SAE SAE reported to instillation IRB Pulmonary embolism 5/l 2/01 Not reported Lethargy, confusion 5125101 Not reported

Page 5 - Dr. Dillman Infected cranial flap, 3/l 9/01 Not reported C. With respect to Study 3, you failed to report SAEs to the IRB within five days as required by the IRB: 1 Subject 1 SAE 1 Date of SAE 1 SAE reported to 1 IRB Abdominal pain 3/25/03, and abdominal 4/l l/03, 5/l o/o3 5119/03 1 mass I We note that Dr a neurosurgeon, extensively participated in Study 1 and is identified as a co-clinica stigator on the Forms FDA-1572 which you signed on 7/7/03 and 12/16/03. If Dr.-assumes and shares responsibility for the study obligations listed on the Form FDA-1572, then Dr lmust also sign the investigator statement, as required by 21 CFR 312.53(c)(l). We note that the informed consent document for Study I, approved by the IRB and signed by subjects-and m states that subjects will be seen in weekly visits for the first month after the infusion of the investigational drug, but the protocol does not require these weekly visits. We recommend that you amend your protocol accordingly. This letter is not intended to contain an all-inclusive list of deficiencies in your clinical studies of investigational drugs, It is your responsibility to ensure adherence to each requirement of the law and applicable regulations and to protect the rights, safety, and welfare of subjects under your care. You should notify this office, in writing, within fifteen (15) business days of receipt of this letter, of the steps you plan to implement to prevent the recurrence of similar violations in future studies and to assure that they are conducted in compliance with 21 CFR Part 312. In your response to the above-mentioned violations, please include supporting documentation. This Warning Letter is issued to you because of the serious nature of the observations noted at the time of the FDA inspection. Please be advised that failure to implement effective corrective actions and/or the commission of further violations may result in the initiation of enforcement action(s) without further notice. These actions could include injunction and/or initiation of clinical investigator disqualification proceedings, which may render you ineligible to receive investigational new drugs.

Page 6 - Dr. Dillman Please send your written response to: Ms. Bhanu Kannan Division of Inspections and Surveillance (HFM-664) Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research Food and Drug Administration 1401. Rockvilfe Pike, Suite 200N Rockville, Maryland, 20852-1448 Telephone: (301) 827-6221 We request that you send a copy of your response to the FDA District Office listed below. Sincerely, Acting Director Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research Alonza E. Cruse, District Director Food and Drug Administration 19701 Fairchild, Suite 300 Irvine, California 92612-2506 Arlene Gwon, M.D., Chair Institutional Review Committee Hoag Memorial Hospital Presbyterian One Hoag Drive, P.O. Box 6100 Newport Beach, California 92658-6100